{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:42:46Z","timestamp":1790775766945,"version":"4.1.0"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.579022","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T06:56:49Z","timestamp":1604645809000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["Targeting the PD-1\/PD-L1 Axis in Human Vitiligo"],"prefix":"10.3389","volume":"11","author":[{"given":"Marcella","family":"Willemsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis J. M.","family":"Melief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel W.","family":"Bekkenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalie M.","family":"Luiten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2001.01408.x","article-title":"Specific cytotoxic T lymphocyte responses against Melan-A\/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex\/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo","volume":"117","author":"Palermo","year":"2001","journal-title":"J Invest Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1034\/j.1600-0749.2003.00023.x","article-title":"Evidence for an autoimmune pathogenesis of vitiligo","volume":"16","author":"Ongenae","year":"2003","journal-title":"Pigment Cell Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.32","article-title":"Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients","volume":"129","author":"van den Boorn","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2006.09.010","article-title":"Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo","volume":"6","author":"Kemp","year":"2007","journal-title":"Autoimmun Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.463","article-title":"A mouse model of vitiligo with focused epidermal depigmentation requires IFN-gamma for autoreactive CD8(+) T-cell accumulation in the skin","volume":"132","author":"Harris","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1755-148X.2011.00920.x","article-title":"Functional defects of peripheral regulatory T lymphocytes in patients with progressive vitiligo","volume":"25","author":"Ben Ahmed","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2014.2436","article-title":"Regulatory T cells from active non-segmental vitiligo exhibit lower suppressive ability on CD8+CLA+ T cells","volume":"24","author":"Lin","year":"2014","journal-title":"Eur J Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.autrev.2014.10.002","article-title":"Regulatory T cells in vitiligo: Implications for pathogenesis and therapeutics","volume":"14","author":"Dwivedi","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.immuni.2017.01.009","article-title":"CD49a Expression Defines Tissue-Resident CD8(+) T Cells Poised for Cytotoxic Function in Human Skin","volume":"46","author":"Cheuk","year":"2017","journal-title":"Immunity"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.08.038","article-title":"Vitiligo Skin Is Imprinted with Resident Memory CD8 T Cells Expressing CXCR3","volume":"138","author":"Boniface","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0298-5","article-title":"Vitiligo: An Update on Pathophysiology and Treatment Options","volume":"18","author":"Speeckaert","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030590","article-title":"Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells","volume":"198","author":"Overwijk","year":"2003","journal-title":"J Exp Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700545","article-title":"Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma","volume":"126","author":"Boasberg","year":"2006","journal-title":"J Invest Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053007","article-title":"Prognostic significance of autoimmunity during treatment of melanoma with interferon","volume":"354","author":"Gogas","year":"2006","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp325","article-title":"Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study","volume":"21","author":"Quaglino","year":"2010","journal-title":"Ann Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12111","article-title":"Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners","volume":"168","author":"Teulings","year":"2013","journal-title":"Br J Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.07.050","article-title":"Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with vitiligo","volume":"71","author":"Paradisi","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18247","article-title":"The incidence and survival of melanoma and nonmelanoma skin cancer in patients with vitiligo: a nationwide population-based matched cohort study in Korea","volume":"182","author":"Kim","year":"2020","journal-title":"Br J Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1419113","article-title":"Anti-Melanoma immunity and local regression of cutaneous metastases in melanoma patients treated with monobenzone and imiquimod; a phase 2 a trial","volume":"7","author":"Teulings","year":"2018","journal-title":"Oncoimmunology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/TP.0000000000000169","article-title":"Co-inhibitory pathways and their importance in immune regulation","volume":"98","author":"Murakami","year":"2014","journal-title":"Transplantation"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu452","article-title":"PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics","volume":"25","author":"Massi","year":"2014","journal-title":"Ann Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/926321","article-title":"Targeting costimulatory molecules to improve antitumor immunity","volume":"2012","author":"Capece","year":"2012","journal-title":"J BioMed Biotechnol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: optimizing outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2019.03.006","article-title":"Application of PD-1 Blockade in Cancer Immunotherapy","volume":"17","author":"Wu","year":"2019","journal-title":"Comput Struct Biotechnol J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000518","article-title":"Cutaneous adverse events of anti-programmed death 1 antibodies combined with anti-cytotoxic T-lymphocyte-associated protein 4 therapy use in patients with metastatic melanoma","volume":"29","author":"Hwang","year":"2019","journal-title":"Melanoma Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13382","article-title":"Vitiligo-like lesions and immune checkpoint inhibition therapy: is it truly an adverse event exclusive to patients with melanoma","volume":"43","author":"Rodriguez-Lomba","year":"2018","journal-title":"Clin Exp Dermatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2017.10.006","article-title":"Immunotherapy \u201cShock\u201d with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma","volume":"22","author":"Zarogoulidis","year":"2017","journal-title":"Respir Med Case Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2016.10.008","article-title":"Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: A novel finding","volume":"3","author":"Yin","year":"2017","journal-title":"JAAD Case Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.04.019","article-title":"Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report","volume":"109","author":"Uenami","year":"2017","journal-title":"Lung Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2018.05.104","article-title":"Nivolumab induced vitiligo-like lesions in a patient with metastatic squamous cell carcinoma of the lung","volume":"10","author":"Nishino","year":"2018","journal-title":"J Thorac Dis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14191","article-title":"Atezolizumab-associated vitiligo-like leukoderma in a patient with transitional cell carcinoma","volume":"57","author":"Turner","year":"2018","journal-title":"Int J Dermatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3488","article-title":"Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab","volume":"25","author":"Hamid","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cellimm.2016.09.009","article-title":"PD-1\/PD-L and autoimmunity: A growing relationship","volume":"310","author":"Zamani","year":"2016","journal-title":"Cell Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.4.1888","article-title":"Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRAIL or programmed death-1 ligand","volume":"174","author":"Hirata","year":"2005","journal-title":"J Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2005.10.017","article-title":"Delivering PD-1 inhibitory signal concomitant with blocking ICOS co-stimulation suppresses lupus-like syndrome in autoimmune BXSB mice","volume":"118","author":"Ding","year":"2006","journal-title":"Clin Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500448","article-title":"Cutting Edge: PD-1 Regulates Imiquimod-Induced Psoriasiform Dermatitis through Inhibition of IL-17A Expression by Innate gammadelta-Low T Cells","volume":"195","author":"Imai","year":"2015","journal-title":"J Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21775","article-title":"Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro","volume":"119","author":"Blank","year":"2006","journal-title":"Int J Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13511","article-title":"Alteration in regulatory T cells and programmed cell death 1-expressing regulatory T cells in active generalized vitiligo and their clinical correlation","volume":"172","author":"Tembhre","year":"2015","journal-title":"Br J Dermatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1172\/JCI36604","article-title":"PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV","volume":"119","author":"Franceschini","year":"2009","journal-title":"J Clin Invest"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13952","article-title":"Expression analysis of PD-1 and Tim-3 immune checkpoint receptors in patients with vitiligo; positive association with disease activity","volume":"28","author":"Rahimi","year":"2019","journal-title":"Exp Dermatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14983","article-title":"Expression of immune checkpoints in active nonsegmental vitiligo: a pilot study","volume":"59","author":"Awad","year":"2020","journal-title":"Int J Dermatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908547","article-title":"Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo","volume":"362","author":"Jin","year":"2010","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/ng.602","article-title":"Common variants in FOXP1 are associated with generalized vitiligo","volume":"42","author":"Jin","year":"2010","journal-title":"Nat Genet"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2272","article-title":"Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo","volume":"44","author":"Jin","year":"2012","journal-title":"Nat Genet"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3680","article-title":"Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants","volume":"48","author":"Jin","year":"2016","journal-title":"Nat Genet"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.05.003","article-title":"Recent insights into the role of the PD-1\/PD-L1 pathway in immunological tolerance and autoimmunity","volume":"12","author":"Gianchecchi","year":"2013","journal-title":"Autoimmun Rev"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02610.x","article-title":"Analysis of a microsatellite polymorphism of the cytotoxic T-lymphocyte antigen-4 gene in patients with vitiligo","volume":"140","author":"Kemp","year":"1999","journal-title":"Br J Dermatol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6364243","article-title":"A single-nucleotide polymorphism in the gene encoding lymphoid protein tyrosine phosphatase (PTPN22) confers susceptibility to generalised vitiligo","volume":"6","author":"Canton","year":"2005","journal-title":"Genes Immun"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1038\/s41598-018-19407-w","article-title":"PD-L1 reverses depigmentation in Pmel-1 vitiligo mice by increasing the abundance of Tregs in the skin","volume":"8","author":"Miao","year":"2018","journal-title":"Sci Rep"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.011","article-title":"Vitiligo: Mechanistic insights lead to novel treatments","volume":"140","author":"Frisoli","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.12.1532","article-title":"Nonsurgical repigmentation therapies in vitiligo. Meta-analysis of the literature","volume":"134","author":"Njoo","year":"1998","journal-title":"Arch Dermatol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1067\/mjd.2001.114752","article-title":"Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo","volume":"44","author":"Scherschun","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-3134","article-title":"Upregulation of PD-L1 via HMGB1-Activated IRF3 and NF-kappaB Contributes to UV Radiation-Induced Immune Suppression","volume":"79","author":"Wang","year":"2019","journal-title":"Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav7431","article-title":"Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy","volume":"12","author":"Mayoux","year":"2020","journal-title":"Sci Transl Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.3390\/cancers11091400","article-title":"Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization","volume":"11","author":"Sun","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96061","article-title":"PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression","volume":"128","author":"Tang","year":"2018","journal-title":"J Clin Invest"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1172\/JCI120803","article-title":"Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression","volume":"128","author":"Lin","year":"2018","journal-title":"J Clin Invest"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.579022\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T06:56:51Z","timestamp":1604645811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.579022\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,6]]},"references-count":64,"alternative-id":["10.3389\/fimmu.2020.579022"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.579022","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,6]]},"article-number":"579022"}}